Fig. 4.

aTLS and dTLS distribution in the FCIS, UCIS, and REST patients groups. a Percentages of patients in the FCIS, REST, and UCIS groups with aTLS-negative (aTLS0) or aTLS-positive (aTLS1–4 and aTLS ≥ 5) tumors and b with dTLS-negative (dTLS0) or dTLS-positive (dTLS +) tumors. c Subgroups in the REST group with aTLS-negative (aTLS0) or aTLS-positive (aTLS1–4 and aTLS ≥ 5) tumors stratified by immune infiltrates in the TC and IM; LL/LL: low number of CD8 + in the TC and IM and low number of CD163 + in the TC and IM; HH/LL: high number of CD8 + in the TC and IM and low number of CD163 + in the TC and IM; HH/HH: high number of CD8 + in the TC and IM and high number of CD163 + in the TC and IM; LL/HH: low number of CD8 + in the TC and IM and high number of CD163 + in the TC and IM. d, e Clinical outcome in patients belonging to the REST group with tumors having aTLS0, aTLS1–4, or TLS ≥ 5. f Statistical analyses among groups